Despite the emerging targeted therapies in treating EGFR-mutated NSCLC, treatment resistance remains a challenge for a subset of patients due to several factors, including reduced sensitivity to TKIs and the presence of concurrent genetic alterations, such as MET amplifications or modifiers of response to TKIs [10]. Here, MET is linked to non-small cell lung carcinoma.